|
Home | Technology News Search Engine:
|
|
|
|
Home: Technology News:
|
|
|
(IT-NEWSWIRE.COM, August 30, 2019 ) Immune Checkpoint Inhibitors Market
• Checkpoint inhibitors block normal proteins on cancer cells or the proteins on T cells. The result is to remove the blinders that prevented T cells from recognizing the cells as cancerous and leading an immune system assault on them.
• Three checkpoint inhibitors have received rapid approval from the U.S. Food and Drug Administration for cancer, including ipilimumab, pembrolizumab, and nivolumab.
Market Dynamics
• According to the National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer in the United States and 609,640 people will die from the disease.
• The number of new cases of cancer is 439.2 per 100,000 men and women per year. The number of cancer deaths is 163.5 per 100,000 men and women per year in the U.S.
• According to Cancer Research U.K., There are more than 360,000 new cancer cases in the UK every year, that’s nearly 990 every day. The incidence rates for all cancers combined are projected to rise by 2% in the UK between 2014 and 2035, to 742 cases per 100,000 people by 2035.
Geographical Analysis
The global immune checkpoint inhibitors market is segmented into
• North America,
• Europe,
• Asia Pacific,
• South America,
• And ROW.
Competitive Trends
• In April 2015, MedImmune, and Juno Therapeutics, Inc., have entered into a new collaboration to conduct combination clinical trials in immuno-oncology with one of Juno’s investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune’s investigational programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor, MEDI4736.
• In August 2018, Ono Pharmaceutical Co. Ltd., have entered into the clinical collaboration agreement with Bristol-Myers Squibb Company and Clovis Oncology Inc. to evaluate the combination therapy of ONO/BMS’s Opdivo, a human anti-human PD-1 monoclonal antibody, and Clovis’ Rubraca8, an inhibitor of poly polymerase (PARP) in multiple tumor types including ovarian cancer, breast cancer and prostate cancer in Japan, South Korea and Taiwan.
Major market players:
Bristol-Myers Squibb Company
Clovis Oncology
others
View full report: https://www.datamintelligence.com/research-report/immune-checkpoint-inhibitors-market
Download free sample: https://www.datamintelligence.com/download-sample/immune-checkpoint-inhibitors-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1-888-702-9626
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
|
Technology News Headlines
|
|
|
|
|
Technology Business Video Feed
|
|
More Technology Video Feeds
|
|
|
